-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Relmada Therapeutics, Inc. annual/quarterly Share-based Payment Arrangement, Expense history and growth rate from Q3 2013 to Q1 2024.
- Relmada Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $8.3M, a 26.9% decline year-over-year.
- Relmada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $30.2M, a 31.1% decline from 2023.
- Relmada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $43.8M, a 0.87% decline from 2022.
- Relmada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $44.2M, a 9.14% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)